Aprea Therapeutics Inc (APRE)
5.00
-0.14
(-2.71%)
USD |
NASDAQ |
Mar 21, 16:00
5.00
0.00 (0.00%)
After-Hours: 20:00
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 13.25M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -85.80% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | 0.4976 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
News
Headline
Wire
Time (ET)
Yahoo
03/16 08:00
Globe Newswire
03/07 08:00
SA Breaking News
03/02 04:21
Globe Newswire
03/01 16:05
Yahoo
02/27 16:05
Globe Newswire
02/22 20:41
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 05/16/2023* | -- | Results | Q1 2023 | -- | -- | -- | |
| 11/09/2022 | -- | Results | Q3 2022 | -2.40 | -1.60 | -50.00% | |
| 08/12/2022 | -- | Results | Q2 2022 | -19.63 | -6.20 | -216.6% | |
| 05/16/2022 | -- | Results | Q1 2022 | -- | -- | -- | |
| 03/15/2022 | -- | Results | Q4 2021 | -- | -- | -- | |
| 11/08/2021 | -- | Results | Q3 2021 | -- | -- | -- | |
| 08/12/2021 | -- | Results | Q2 2021 | -- | -- | -- | |
| 05/06/2021 | -- | Results | Q1 2021 | -- | -- | -- |
*Estimated Date/Time
Earnings
Profile
Edit
| Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its product candidate, APR-246, is a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML). |
| URL | https://www.aprea.com |
| Investor Relations URL | https://ir.aprea.com/ |
| HQ State/Province | Massachusetts |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | May. 16, 2023 (est.) |
| Last Earnings Release | Nov. 09, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0% |
| Forward Yield | -- |
| Payout Ratio | -- |
| Cash Payout Ratio | -- |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk
Total Returns Comparison
Annual Total Returns Versus Peers
As of March 20, 2023.
Fundamentals
2017
2018
2019
2020
2021
4.00
2.00
1.00
| Revenue (TTM) | -- |
| Total Expenses (TTM) | 42.55M |
| Net Income (TTM) | -117.98M |
| Total Assets (Quarterly) | 33.62M |
| Total Liabilities (Quarterly) | 6.997M |
| Shareholders Equity (Quarterly) | 26.63M |
| Cash from Operations (TTM) | -31.17M |
| Cash from Investing (TTM) | 0.00 |
| Cash from Financing (TTM) | 2.244M |
Ratings
Profile
Edit
| Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its product candidate, APR-246, is a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML). |
| URL | https://www.aprea.com |
| Investor Relations URL | https://ir.aprea.com/ |
| HQ State/Province | Massachusetts |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | May. 16, 2023 (est.) |
| Last Earnings Release | Nov. 09, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| APRE Tweets |